Abortion rights groups, funds and providers have been left to grapple with the uncertain future of medication abortion after a pair of competing federal court rulings Friday. 

Melissa Fowler, chief program officer at the National Abortion Federation, said a ruling in Texas to halt FDA approval of mifepristone is “sowing chaos and confusion for abortion seekers.” Fowler emphasized the safety and effectiveness of mifepristone, which has been long hailed as safe by federal regulators and medical associations.

WHAT’S NEXT:Mifepristone rulings set up first major post-Roe abortion case at Supreme Court

WATCH:Vice President Harris reacts to Texas federal judge’s ruling on abortion pill

The chaotic legal landscape is expected to rapidly change over the next week. But for now “nothing changes at all with respect to the availability of mifepristone,” said Andrew Beck, senior staff attorney with the ACLU’s reproductive freedom project.

But what comes next is unclear.

In the meantime, abortion providers and advocates across the nation have reported another round of confusion and frustration. 

BACKGROUND:Who is Judge Matthew Kacsmaryk and why was the abortion pill case in his court?

Want an abortion?:Here are options for pregnant people if mifepristone is suspended

FRIDAY:Dueling federal rulings plunge future of abortion pill into legal uncertainty

“We have patients coming in for abortion services in our clinics today, so we had to know quickly what this meant for us,” Andrea Ferrigno, corporate vice president for Whole Woman’s Health, a network of abortion clinics, said. “For patients, this is just another level of frustration, stress and confusion during an already stressful time.”

Whole Woman’s Health, which offers care in Minnesota, Virginia, Maryland, Indiana, New Mexico and Illinois, is among several abortion providers who told USA TODAY they would continue offering mifepristone for the time being. If clinics eventually lose access to the drug, many providers, including Whole Woman’s Health, said they would pivot to misoprostol-only care. Some have also said they may open more appointments for in-clinic, procedural abortions.